International Journal of Radiation Oncology * Biology * Physics
Volume 67, Issue 1 , Pages 6-9 , 1 January 2007

Administration of the peroxisomal proliferator-activated receptor γ agonist pioglitazone during fractionated brain irradiation prevents radiation-induced cognitive impairment

  • Weiling Zhao, Ph.D.

      Affiliations

    • Department of Radiation Oncology, Brain Tumor Center of Excellence, Wake Forest University School of Medicine, Winston-Salem, NC
  • ,
  • Valerie Payne, B.S.

      Affiliations

    • Department of Radiation Oncology, Brain Tumor Center of Excellence, Wake Forest University School of Medicine, Winston-Salem, NC
  • ,
  • Ellen Tommasi, B.S.

      Affiliations

    • Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, NC
  • ,
  • Debra I. Diz, Ph.D.

      Affiliations

    • Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, NC
  • ,
  • Fang-Chi Hsu, Ph.D.

      Affiliations

    • Department of Biostatistical Sciences, Wake Forest University School of Medicine, Winston-Salem, NC
  • ,
  • Mike E. Robbins, Ph.D.

      Affiliations

    • Department of Radiation Oncology, Brain Tumor Center of Excellence, Wake Forest University School of Medicine, Winston-Salem, NC
    • Corresponding Author InformationReprint requests to: Mike E. Robbins, M.D., Room 412C NRC, Department of Radiation Oncology, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157. Tel: (336) 713-7635; Fax: (336) 713-7639

Received 15 September 2006 ,Revised 21 September 2006 ,Accepted 22 September 2006.

References 

  1. Meyers CA, Brown PD. Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol. 2006;24:1305–1309
  2. Patchell RA. The management of brain metastases. Cancer Treat Rev. 2003;29:533–540
  3. Robbins MEC, Zhao W. Chronic oxidative stress and radiation-induced late normal tissue injury: A review. Int J Radiat Biol. 2004;80:251–259
  4. Lemberger T, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: A nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Develop Biol. 1996;12:335–363
  5. Bishop-Bailey D. Peroxisomer proliferator-activated receptors in the cardiovascular system. Br J Pharmacol. 2000;129:823–834
  6. Francis GA, Annicotte J-S, Auwerx J. PPAR agonists in the treatment of atherosclerosis. Curr Opin Pharmacol. 2003;3:186–191
  7. Feinstein DL. Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. Diabetes Technol Ther. 2003;5:67–73
  8. Brown WR, Thore CR, Moody DM, et al. Vascular damage after fractionated whole-brain irradiation in rats. Radiat Res. 2005;164:662–668
  9. Clark RE, Martin SJ. Interrogating rodents regarding their object and spatial memory. Curr Opin Neurobiol. 2005;15:593–598
  10. Kasper SO, Carter CS, Ferrario CM, et al. Growth, metabolism, and blood pressure disturbances during aging in transgenic rats with altered brain renin-angiotensin systems. Physiol Genomics. 2005;23:311–317
  11. Yoneoka Y, Satch M, Akiyama K, et al. An experimental study of radiation-induced cognitive dysfunction in an adult rat model. Br J Radiol. 1999;72:1196–1201
  12. Shi L, Adams MA, Long A, et al. Spatial learning and memory deficits following whole brain irradiation are associated with changes in NMDA receptor subunits in the hippocampus. Radiat Res, in press.
  13. Bordet R, Gelé P, Duriez P, et al. PPARs: A new target for neuroprotection. J Neurol Neurosurg Pschiatry. 2006;77:285–287
  14. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists. Lancet Oncol. 2004;5:419–429

 Supported by National Institutes of Health grants CA112593 (MER) and HL51952 (DIZ).Conflict of interest: none.

PII: S0360-3016(06)03128-2

doi: 10.1016/j.ijrobp.2006.09.036

International Journal of Radiation Oncology * Biology * Physics
Volume 67, Issue 1 , Pages 6-9 , 1 January 2007